A year after the identification of the JAK2 mutation as a pivotal factor in the pathogenesis of myeloproliferative neoplasms (MPN), researchers began to investigate patients lacking JAK2 alterations. This evidence concerns the gene JAK2 and myeloproliferative disorder.